-
Company Insights
Innovation and Patenting activity of NOS SGPS SA Q4 2023
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of NOS SGPS SA Q4 2023". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will be...
-
Sector Analysis
NewPortugal Telecom Operators Country Intelligence Report
Portugal Telecom Operators Country Intelligence Overview The total telecom and pay-TV service revenue in Portugal was $5 billion in 2023. The total telecom and pay-TV service revenue in Portugal reached $5 billion in 2023. The market size growth has been estimated to decline at a CAGR of less than 1% during 2023-2028. Portugal Telecom Services Market Outlook, 2023-2028 ($ Billion) Buy the Full Report to Gain More Information on the Portugal Telecom Services Market Forecast Download a Free Sample The...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – 2-Iminobiotin in Acute Ischemic Stroke
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - 2-Iminobiotin in Acute Ischemic Stroke report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. 2-Iminobiotin in Acute Ischemic Stroke Drug Details: 2-Iminobiotin is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – WU-CART-007 in T-Cell Lymphomas
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - WU-CART-007 in T-Cell Lymphomas report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. WU-CART-007 in T-Cell Lymphomas Drug Details: WU-CART-007 is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – WU-CART-007 in T-Cell Leukemia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - WU-CART-007 in T-Cell Leukemia report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. WU-CART-007 in T-Cell Leukemia Drug Details: WU-CART-007 is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – WU-CART-007 in Sezary Syndrome
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - WU-CART-007 in Sezary Syndrome report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. WU-CART-007 in Sezary Syndrome Drug Details: WU-CART-007 is under development for the...
-
New
Likelihood of Approval and Phase Transition Success Rate Model – WU-CART-007 in Peripheral T-Cell Lymphomas (PTCL)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - WU-CART-007 in Peripheral T-Cell Lymphomas (PTCL) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. WU-CART-007 in Peripheral T-Cell Lymphomas (PTCL) Drug Details: WU-CART-007 is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – WU-CART-007 in Angioimmunoblastic T-Cell Lymphoma (AITL)/Immunoblastic Lymphadenopathy
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - WU-CART-007 in Angioimmunoblastic T-Cell Lymphoma (AITL)/Immunoblastic Lymphadenopathy report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. WU-CART-007 in Angioimmunoblastic T-Cell Lymphoma (AITL)/Immunoblastic Lymphadenopathy Drug Details:...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – WU-CART-007 in Anaplastic Large Cell Lymphoma (ALCL)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - WU-CART-007 in Anaplastic Large Cell Lymphoma (ALCL) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. WU-CART-007 in Anaplastic Large Cell Lymphoma (ALCL) Drug Details:...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – WU-CART-007 in Refractory Acute Myeloid Leukemia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - WU-CART-007 in Refractory Acute Myeloid Leukemia report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. WU-CART-007 in Refractory Acute Myeloid Leukemia Drug Details: WU-CART-007 is...